Proxy Filed for $437M All-Cash Acquisition by Knox Lane at $13.25/Share, Details Executive Payouts
CCRN sits 77% above its 52-week low of $7.43.
Summary
Cross Country Healthcare filed its preliminary proxy statement for the upcoming shareholder vote on its all-cash acquisition by Knox Lane for $13.25 per share, detailing the board's recommendation, financial advisor's opinion, and executive merger-related compensation.
Key Events · M&A and Partnerships · CCRN
-
Shareholder Vote on Acquisition
The company is seeking shareholder approval for its acquisition by KL Criss Cross Intermediate, LLC (an affiliate of Knox Lane LP) for $13.25 per share in cash. A majority of outstanding shares is required for approval.
-
Significant Acquisition Premium
The $13.25 per share merger consideration represents an approximately 31% premium to the closing price on May 6, 2026, and a 45% premium to the 90-day volume-weighted average trading price prior to the announcement.
-
Board Unanimously Recommends Merger
The Cross Country board of directors unanimously determined the merger is fair and in the best interests of shareholders, recommending a 'FOR' vote on all related proposals.
-
Executive Merger-Related Compensation
Named executive officers are eligible for significant 'golden parachute' payments upon a qualifying termination post-merger, including approximately $11.1 million for CEO Kevin C. Clark, $5.01 million for CFO William J. Burns, $3.99 million for EVP Susan E. Ball, and $2.19 million for Group President Marc S. Krug.
Analysis · CCRN · Trade & Services
This preliminary proxy statement provides shareholders with the full details and rationale for the proposed all-cash acquisition of Cross Country Healthcare by Knox Lane for $13.25 per share. The acquisition, previously announced on May 6, 2026, offers a substantial premium of approximately 31% over the last unaffected closing price, providing a clear exit for shareholders amidst the company's recent financial struggles, including significant net losses and revenue declines reported in its latest 10-K and 10-Q filings. The filing also details significant 'golden parachute' compensation for executive officers, totaling over $22 million, which is a material consideration for shareholders voting on the merger. This is a critical step towards the consummation of a major corporate event.
At the time of this filing, CCRN was trading at $13.12 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $424.2M. The 52-week trading range was $7.43 to $14.99. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.